Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 703

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

European S3‐Guidelines on the systemic treatment of psoriasis vulgaris: Supported by the EDF/EADV/IPC

Open access
Pathirana, D, Ormerod, AD, Saiag, P, Smith, C, Spuls, PI, Nast, A, Barker, J, Bos, JD, Burmester, G‐R, Chimenti, S, Dubertret, L, Eberlein, B, Erdmann, R, Ferguson, J, Girolomoni, G, Gisondi, P, Giunta, A, Griffiths, C, Hönigsmann, H, Hussain, M, Jobling, R, Karvonen, S‐L, Kemeny, L, Kopp, I, Leonardi, C, Maccarone, M, Menter, A, Mrowietz, U, Naldi, L, Nijsten, T, Ortonne, J‐P, Orzechowski, H‐D, Rantanen, T, Reich, K, Reytan, N, Richards, H, Thio, HB, Van De Kerkhof, P, Rzany, B·2009·Journal of the European Academy of Dermatology and Venereology
DOI 10.1111/j.1468-3083.2009.03389.x
Open this paper in CoChat — free account

Abstract

Of the 131 studies on monotherapy or combination therapy assessed, 56 studies on the different forms of phototherapy fulfilled the criteria for inclusion in the guidelines. Approximately three-quarters of all patients treated with phototherapy attained at least a PASI 75 response after 4 to 6 weeks, and clearance was frequently achieved (levels of evidence 2 and 3). Phototherapy represents a safe and very effective treatment option for moderate to severe forms of psoriasis vulgaris. The onset of clinical effects occurs within 2 weeks. Of the unwanted side effects, UV erythema from overexposure is by far the most common and is observed frequently. With repeated or long-term use, the consequences of high, cumulative UV doses (such as premature aging of the skin) must be taken into consideration. In addition, carcinogenic risk is associated with oral PUVA and is probable for local PUVA and UVB. The practicability of the therapy is limited by spatial, financial, human, and time constraints on the part of the physician, as well as by the amount of time required by the patient. From the perspective of the cost-bearing institution, phototherapy has a good cost-benefit ratio. However, the potentially significant costs for, and time required of, the patient must be considered.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1468-3083.2009.03389.x

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 703

Metadata

Authors
Pathirana, D., Ormerod, A., Saiag, P., Smith, C., Spuls, P., Nast, A., Barker, J., Bos, J., Burmester, G., Chimenti, S., Dubertret, L., Eberlein, B., Erdmann, R., Ferguson, J., Girolomoni, G., Gisondi, P., Giunta, A., Griffiths, C., Hönigsmann, H., Hussain, M., Jobling, R., Karvonen, S., Kemeny, L., Kopp, I., Leonardi, C., Maccarone, M., Menter, A., Mrowietz, U., Naldi, L., Nijsten, T., Ortonne, J., Orzechowski, H., Rantanen, T., Reich, K., Reytan, N., Richards, H., Thio, H., Van De Kerkhof, P., & Rzany, B.
Venue
Journal of the European Academy of Dermatology and Venereology
Publisher
Wiley
Published
2009-08-26
Volume
23
Issue
s2
Pages
1-70
ISSN
  • 0926-9959 (ISSN-L)
  • 1468-3083
DOI
10.1111/j.1468-3083.2009.03389.x
OpenAlex
W2069350424
Cited by
703
References
6
FWCI
21.13
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: European S3‐Guidelines on the systemic treatment of psoriasis vulgaris: Supported by the EDF/EADV/IPC. https://app.cochat.ai/papers/10.1111/j.1468-3083.2009.03389.x
The paper
Pathirana, D., Ormerod, A., Saiag, P., Smith, C., Spuls, P., Nast, A., Barker, J., Bos, J., Burmester, G., Chimenti, S., Dubertret, L., Eberlein, B., Erdmann, R., Ferguson, J., Girolomoni, G., Gisondi, P., Giunta, A., Griffiths, C., Hönigsmann, H., . . . Rzany, B. (2009). European S3‐Guidelines on the systemic treatment of psoriasis vulgaris: Supported by the EDF/EADV/IPC. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/j.1468-3083.2009.03389.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.